Premium
Glutathione‐Mediated Degradation of Surface‐Capped MnO 2 for Drug Release from Mesoporous Silica Nanoparticles to Cancer Cells
Author(s) -
Yang Xue,
He Dinggeng,
He Xiaoxiao,
Wang Kemin,
Zou Zhen,
Li Xuecai,
Shi Hui,
Luo Jierong,
Yang Xiaoxiao
Publication year - 2015
Publication title -
particle and particle systems characterization
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.877
H-Index - 56
eISSN - 1521-4117
pISSN - 0934-0866
DOI - 10.1002/ppsc.201400092
Subject(s) - glutathione , mesoporous silica , drug delivery , chemistry , doxorubicin , cancer cell , biophysics , cytotoxicity , intracellular , nanoparticle , in vitro , nanotechnology , combinatorial chemistry , mesoporous material , biochemistry , materials science , cancer , organic chemistry , chemotherapy , biology , enzyme , catalysis , genetics
Owing to its higher concentration in cancer cells than that in the corresponding normal cells, glutathione (GSH) provides an effective and flexible mechanism to design drug delivery systems. Here a novel GSH‐responsive mesoporous silica nanoparticle (MSN) is reported for controlled drug release. In this system, manganese dioxide (MnO 2 ) nanostructure, formed by the reduction of KMnO 4 on the surface of carboxyl‐functionalized MSN can block the pores (MSN@MnO 2 ). By a redox reaction, the capped MnO 2 nanostructure can dissociate into Mn 2+ in the presence of GSH molecules. The blocked pores are then uncapped, which result in the release of the entrapped drugs. As a proof‐of‐concept, doxorubicin (DOX) as model drug is loaded into MSN@MnO 2 . DOX‐loaded MSN@MnO 2 shows an obvious drug release in 10 × 10 −3 m GSH, while no release is observed in the absence of GSH. In vitro studies using human hepatocellular liver carcinoma cell line (HepG2) prove that the DOX‐loaded MSN@MnO 2 can entry into HepG2 cells and efficiently release the loaded DOX, leading to higher cytotoxicity than to that of human normal liver cells (L02). It is believed that further developments of this GSH‐responsive drug delivery system will lead to a new generation of nanodevices for intracellular controlled delivery.